Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

Commentary
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

In an interview with CancerNetwork®, William Kennedy, MD, a neuro-radiation oncologist at the Ivy Brain Tumor Center, provided expert insights into the current state of radiosurgery for central nervous system (CNS) tumors. Highlighting a diverse array of available radiosurgery platforms, he explained that institutions like the Ivy Brain Tumor Center frequently use noninvasive surgical techniques with complex monitoring systems.

Kennedy further underscored the critical importance of having a nuanced understanding of each technology's capabilities and limitations, as well as those of the practicing oncologist. Emphasizing a high patient volume and a wide variety of cases at his own practice, he suggested that the expertise of the staff at the Ivy Brain Tumor Center positions them at the forefront of radiosurgery development.

According to Kennedy, novel therapeutic strategies under development at Ivy Brain Tumor Center include the investigational agent AZD1390, which is being assessed in combination with radiotherapy after surgery for patients with newly diagnosed or recurrent glioblastoma.

Despite the benefits that technology provide for research advancement and treatment, Kennedy posited that the multidisciplinary team is essential in ensuring the successful delivery of novel radiosurgery techniques. This integrated approach ensures that each patient benefits from an individualized plan that leverages the full potential of modern radiosurgery.

“[D]espite all the great technologies that we have here at Ivy, what I think makes this place great, what makes me proud to work here, and what means the most for our patients is how closely we providers communicate with each other and how closely knit of a team we are,” Kennedy stated. “Being available, showing up to the tumor board, always picking up the phone when your colleague calls to discuss a tough case, and never being afraid to ask for help—all those things I have learned since I have been in practice here. Those are what make the difference, more than anything.”

Recent Videos
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
Related Content